Cervical Cancer Screening in Partly HPV Vaccinated Cohorts – A Cost-Effectiveness Analysis
出版年份 2016 全文链接
标题
Cervical Cancer Screening in Partly HPV Vaccinated Cohorts – A Cost-Effectiveness Analysis
作者
关键词
Immunity, Cervical cancer, Human papillomavirus, Vaccination and immunization, Cancer screening, Cancer vaccines, Lesions, Screening guidelines
出版物
PLoS One
Volume 11, Issue 1, Pages e0145548
出版商
Public Library of Science (PLoS)
发表日期
2016-01-30
DOI
10.1371/journal.pone.0145548
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
- (2015) Mélanie Drolet et al. LANCET INFECTIOUS DISEASES
- Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
- (2014) Sepehr N Tabrizi et al. LANCET INFECTIOUS DISEASES
- Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study
- (2014) Alejandra Castañón et al. PLOS MEDICINE
- Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement
- (2013) Virginia A. Moyer ANNALS OF INTERNAL MEDICINE
- Health-related quality of life and perception of anxiety in women with abnormal cervical cytology referred for colposcopy: an observational study
- (2013) Annu Heinonen et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach
- (2013) Julia M L Brotherton et al. MEDICAL JOURNAL OF AUSTRALIA
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
- (2012) Debbie Saslow et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing
- (2012) J van Rosmalen et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
- (2012) E A Burger et al. BRITISH JOURNAL OF CANCER
- Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
- (2012) Peng Guan et al. INTERNATIONAL JOURNAL OF CANCER
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- (2012) Talía Malagón et al. LANCET INFECTIOUS DISEASES
- Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening
- (2012) Veerle M.H. Coupé et al. VACCINE
- A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
- (2012) John T. Schiller et al. VACCINE
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
- (2012) Beatriz Serrano et al. Infectious Agents and Cancer
- Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
- (2011) Marc Brisson et al. JOURNAL OF INFECTIOUS DISEASES
- Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis
- (2011) Gabriele Accetta et al. JOURNAL OF MEDICAL SCREENING
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial
- (2011) Dorien C Rijkaart et al. LANCET ONCOLOGY
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Cost-effectiveness of human papillomavirus vaccination and screening in Spain
- (2010) Mireia Diaz et al. EUROPEAN JOURNAL OF CANCER
- Pathology and epidemiology of HPV infection in females
- (2010) Margaret Stanley GYNECOLOGIC ONCOLOGY
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
- (2010) Nubia Muñoz et al. JNCI-Journal of the National Cancer Institute
- Understanding the Reasons Why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against Human Papillomavirus
- (2009) Amanda F. Dempsey et al. ANNALS OF EPIDEMIOLOGY
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom
- (2009) Yoon Hong Choi et al. VACCINE
- Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening
- (2008) V M H Coupé et al. BRITISH JOURNAL OF CANCER
- Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination
- (2008) J. D. Goldhaber-Fiebert et al. JNCI-Journal of the National Cancer Institute
- Sexual Behaviour and HPV Infections in 18 to 29 Year Old Women in the Pre-Vaccine Era in the Netherlands
- (2008) Charlotte H. Lenselink et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More